Agios Pharmaceuticals annual operating margin
2011
2012
2013
2014
2015
2016
2017
2018
2019
2022
2023
2024
2025
Agios Pharmaceuticals's operating margin was −873.87% for fiscal 2025.
View full Agios Pharmaceuticals company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −873.87% | +292.60 pp |
| 2024 | 2024-12-31 | −1,166.47% | +293.05 pp |
| 2023 | 2023-12-31 | −1,459.52% | +1272.55 pp |
| 2022 | 2022-12-31 | −2,732.07% | −2463.85 pp |
| 2019 | 2019-12-31 | −268.22% | +115.81 pp |
| 2018 | 2018-12-31 | −384.03% | +361.81 pp |
| 2017 | 2017-12-31 | −745.84% | −458.28 pp |
| 2016 | 2016-12-31 | −287.57% | −86.78 pp |
| 2015 | 2015-12-31 | −200.78% | −117.96 pp |
| 2014 | 2014-12-31 | −82.83% | +69.37 pp |
| 2013 | 2013-12-31 | −152.20% | −60.60 pp |
| 2012 | 2012-12-31 | −91.59% | −15.43 pp |
| 2011 | 2011-12-31 | −76.16% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −247.07% | +773.05 pp |
| Q1 2026 | 2026-03-31 | −530.34% | +691.63 pp |
| Q4 2025 | 2025-12-31 | −608.89% | +556.41 pp |
| Q3 2025 | 2025-09-30 | −907.37% | +239.56 pp |
| Q2 2025 | 2025-06-30 | −1,020.12% | +208.17 pp |
| Q1 2025 | 2025-03-31 | −1,221.97% | −97.63 pp |
| Q4 2024 | 2024-12-31 | −1,165.30% | +330.92 pp |
| Q3 2024 | 2024-09-30 | −1,146.93% | +216.73 pp |
| Q2 2024 | 2024-06-30 | −1,228.29% | +167.72 pp |
| Q1 2024 | 2024-03-31 | −1,124.34% | +491.16 pp |
| Q4 2023 | 2023-12-31 | −1,496.23% | +804.75 pp |
| Q3 2023 | 2023-09-30 | −1,363.66% | +1227.07 pp |
| Q2 2023 | 2023-06-30 | −1,396.01% | +353.19 pp |
| Q1 2023 | 2023-03-31 | −1,615.49% | +10541.36 pp |
| Q4 2022 | 2022-12-31 | −2,300.97% | −2069.63 pp |
| Q3 2022 | 2022-09-30 | −2,590.73% | −2367.78 pp |
| Q2 2022 | 2022-06-30 | −1,749.19% | −1649.27 pp |
| Q1 2022 | 2022-03-31 | −12,156.85% | −12168.52 pp |
| Q3 2020 | 2020-09-30 | −231.34% | +187.73 pp |
| Q2 2020 | 2020-06-30 | −222.95% | +211.29 pp |
| Q1 2020 | 2020-03-31 | −99.92% | +222.58 pp |
| Q4 2019 | 2019-12-31 | 11.67% | +332.72 pp |
| Q3 2019 | 2019-09-30 | −419.07% | +233.39 pp |
| Q2 2019 | 2019-06-30 | −434.24% | −253.73 pp |
| Q1 2019 | 2019-03-31 | −322.50% | +750.45 pp |
| Q4 2018 | 2018-12-31 | −321.05% | +598.74 pp |
| Q3 2018 | 2018-09-30 | −652.47% | +43.23 pp |
| Q2 2018 | 2018-06-30 | −180.50% | +565.13 pp |
| Q1 2018 | 2018-03-31 | −1,072.95% | −434.89 pp |
| Q4 2017 | 2017-12-31 | −919.79% | −212.92 pp |
| Q3 2017 | 2017-09-30 | −695.69% | +113.56 pp |
| Q2 2017 | 2017-06-30 | −745.64% | −527.42 pp |
| Q1 2017 | 2017-03-31 | −638.06% | −491.82 pp |
| Q3 2016 | 2016-09-30 | −706.87% | −523.60 pp |
| Q2 2016 | 2016-06-30 | −809.26% | −632.66 pp |
| Q2 2014 | 2014-06-30 | −218.21% | −82.88 pp |
| Q1 2014 | 2014-03-31 | −146.24% | −34.40 pp |
| Q4 2013 | 2013-12-31 | −183.26% | −101.74 pp |
| Q3 2013 | 2013-09-30 | −176.60% | −79.22 pp |
| Q2 2013 | 2013-06-30 | −135.33% | — |
| Q1 2013 | 2013-03-31 | −111.84% | — |
| Q3 2012 | 2012-09-30 | −81.53% | — |
| Q2 2012 | 2012-06-30 | −97.38% | — |
Over the last five reported fiscal years, Agios Pharmaceuticals's operating margin decreased from −384.03% to −873.87%, a change of −489.83 percentage points. The latest reported quarter, Q2 2026, shows −247.07%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Agios Pharmaceuticals filings at SEC.gov ↗